L3VLUP
ProSign in

BAX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BAXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BAX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterBAXJNJ
Q3 202029 holders, $4.9bn30 holders, $26.2bn
Q4 202023 holders, $6.3bn32 holders, $26.6bn
Q1 202119 holders, $7.5bn31 holders, $25.3bn
Q2 202127 holders, $7.0bn37 holders, $25.6bn
Q3 202124 holders, $6.6bn40 holders, $24.1bn
Q4 202121 holders, $6.9bn33 holders, $25.2bn
Q1 202226 holders, $6.5bn35 holders, $28.2bn
Q2 202219 holders, $5.3bn33 holders, $26.9bn
Q3 202216 holders, $4.3bn36 holders, $25.4bn
Q4 202223 holders, $3.2bn35 holders, $27.6bn
Q1 202326 holders, $2.4bn42 holders, $24.5bn
Q2 202324 holders, $2.7bn38 holders, $25.0bn
Q3 202317 holders, $2.3bn37 holders, $18.9bn
Q4 202315 holders, $2.8bn31 holders, $19.0bn
Q1 202415 holders, $3.1bn32 holders, $19.7bn
Q2 202412 holders, $2.3bn35 holders, $20.4bn
Q3 20249 holders, $3.2bn28 holders, $22.3bn
Q4 20248 holders, $2.6bn37 holders, $20.4bn
Q1 20259 holders, $3.3bn32 holders, $20.5bn
Q2 20258 holders, $2.8bn31 holders, $18.4bn
Q3 202511 holders, $2.0bn32 holders, $23.7bn
Q4 20259 holders, $2.1bn29 holders, $27.8bn
Q1 20266 holders, $1.9bn34 holders, $35.6bn
Q2 202610 holders, $2.6bn33 holders, $39.1bn
BAX

Baxter Intl Inc

Holders
15
Reported value
$2.8bn
Buyers
7
Sellers
10

Breadth -3 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$19.0bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BAX (4)

Artisan Partners LP, Harris Associates LP, Holocene Advisors LP, Maverick Capital Ltd

Only JNJ (20)

Acadian Asset Management LLC, AllianceBernstein LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Jane Street Group LLC, Man Group PLC, Markel Group Inc, MFS Investment Management, Neuberger Berman Group LLC, Quantbot Technologies LP, Squarepoint Ops LLC, Susquehanna International Group LLP, Tudor Investment Corp, Verition Fund Management LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →